<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5571507</article-id><article-id pub-id-type="pmid">28836955</article-id><article-id pub-id-type="publisher-id">2695</article-id><article-id pub-id-type="doi">10.1186/s12879-017-2695-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tengan</surname><given-names>Fatima Mitiko</given-names></name><address><email>fatima.tengan@uol.com.br</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Abdala</surname><given-names>Edson</given-names></name><address><email>eabdala@uol.com.br</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nascimento</surname><given-names>Marisa</given-names></name><address><email>marisa.nascimento@hc.fm.usp.br</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bernardo</surname><given-names>Wanderley Marques</given-names></name><address><email>wmbernardo@usp.br</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Barone</surname><given-names>Antonio Alci</given-names></name><address><email>aabarone@uol.com.br</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution>Department of Infectious and Parasitic Diseases, School of Medicine, </institution><institution>University of S&#x000e3;o Paulo (Universidade de S&#x000e3;o Paulo - USP), </institution></institution-wrap>S&#x000e3;o Paulo, Brazil </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution>Laboratory of Viral Medical Research in Hepatology (Laborat&#x000f3;rio de Investiga&#x000e7;&#x000e3;o M&#x000e9;dica em Hepatologia por v&#x000ed;rus - LIM-47), Clinical Hospital, School of Medicine, </institution><institution>USP, </institution></institution-wrap>S&#x000e3;o Paulo, Brazil </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution>Nursing Division, Clinics Hospital, School of Medicine, </institution><institution>USP, </institution></institution-wrap>S&#x000e3;o Paulo, SP Brazil </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0722</institution-id><institution-id institution-id-type="GRID">grid.11899.38</institution-id><institution>School of Medicine, </institution><institution>USP, </institution></institution-wrap>S&#x000e3;o Paulo, Brazil </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9378 7383</institution-id><institution-id institution-id-type="GRID">grid.470792.f</institution-id><institution/><institution>Brazilian Medical Association, </institution></institution-wrap>Sao Paulo, Brazil </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>587</elocation-id><history><date date-type="received"><day>13</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hepatitis B virus (HBV) infection is a major cause of chronic liver disease worldwide. In immunocompromised patients, the chronicity rates of HBV infection are higher, but the rates of hepatitis Be antigen (HBeAg) and HBsAg loss and seroconversion to anti-HBe and anti-HBs are lower than those in immunocompetent subjects. This study aimed to evaluate articles on the prevalence of HBsAg in people living with human immunodeficiency virus (HIV) /AIDS (PLWHA) in Latin America and the Caribbean (LAC).</p></sec><sec><title>Methods</title><p id="Par2">We searched the PubMed, Latin American and Caribbean Health Sciences, and Embase databases for studies up to November 2016 on infection with HIV and HBV in LAC without period or language restrictions. We did not include case reports, case series, review articles, comments, or studies with a sample size smaller than 100. We also evaluated the quality of the articles using a list of criteria totaling 21 items.</p></sec><sec><title>Results</title><p id="Par3">Of the 28 selected articles (<italic>n</italic>&#x000a0;=&#x000a0;18,457) published from 1999 to 2016, 18 studies (64.3%) were from Brazil, 3 (10.7%) were from Argentina, 2 (7.1%) were from Chile, 2 (7.1%) were from Cuba, 1 (3.6%) was from Colombia, 1 (3.6%) was from Venezuela, and 1 (3.6%) was from Jamaica. The mean score for the assessment of the study quality was 11.6 (range: 8&#x02013;16). The estimated pooled prevalence of HBsAg among PLWHA in the selected studies was 7.0% (95% CI 7.0&#x02013;7.0%). The pooled prevalence of HBsAg was 8.0% (95% CI 8.0&#x02013;9.0%) in the studies published from 1999 to 2006 and 6.0% (95% CI 5.0&#x02013;6.0%) in the studies published during the later timeframe.</p></sec><sec><title>Conclusions</title><p id="Par4">The results of this review indicate the need to increase the investment in preventive measures against hepatitis B, particularly when the impact of adequate vaccination in this population is considered. Future studies with larger sample sizes are needed in LAC to determine the true prevalence of hepatitis B throughout the region and to clarify and address the risk factors associated with the acquisition of infection.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12879-017-2695-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis B</kwd><kwd>Hepatitis B virus</kwd><kwd>HIV</kwd><kwd>Human immunodeficiency virus</kwd><kwd>Latin America</kwd><kwd>The Caribbean</kwd><kwd>Prevalence</kwd><kwd>Systematic review</kwd><kwd>Review</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par10">Hepatitis B virus (HBV) infection is a major cause of chronic liver disease worldwide, and approximately 350 million people are chronically infected. In the absence of antiviral therapy, 15% to 40% of patients positive for the hepatitis B surface antigen (HBsAg) develop progressive liver disease, cirrhosis, hepatocellular carcinoma, and terminal liver failure [<xref ref-type="bibr" rid="CR1">1</xref>]. Because HBV is primarily transmitted via the parenteral and sexual routes and during the perinatal period similar to human immunodeficiency virus (HIV), coinfection with HIV and HBV is common [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par11">HIV infection appears to have a negative impact on the natural history of HBV infection. In immunocompromised patients, the chronicity rates of HBV infection are higher, but the rates of hepatitis Be antigen (HBeAg) and HBsAg loss and seroconversion to anti-HBe and anti-HBs are lower than those in immunocompetent subjects [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par12">Patients with HIV infection have lower serum alanine aminotransferase and albumin levels and higher serum HBV DNA levels than patients with HBV monoinfection. Additionally, the prevalence of cirrhosis is higher in HIV-positive patients [<xref ref-type="bibr" rid="CR6">6</xref>]. Coinfection with HIV and HBV is associated with a higher rate of HBV reactivation and an increased incidence of cirrhosis and death from cirrhosis in cases with low CD4 counts. Coinfection is also associated with a higher incidence of hepatocellular carcinoma [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par13">Other studies have suggested that HBV is associated with a rapidly progressive course of HIV infection [<xref ref-type="bibr" rid="CR9">9</xref>]. A retrospective analysis indicated that the risk of death in 64 individuals coinfected with HIV and HBV was approximately two-fold higher than that in individuals with HIV monoinfection [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par14">The estimated prevalence of hepatitis B among people living with HIV/AIDS (PLWHA) is 5&#x02013;20%. Therefore, approximately 2 to 4 million people living with HIV have chronic hepatitis B coinfection [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Although several studies have evaluated the prevalence of hepatitis B in PLWHA in Latin America and the Caribbean (LAC), the results are conflicting among the evaluated regions and even within the same geographic area. This study aimed to evaluate the studies on the prevalence of HBsAg in LAC countries or territories.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par15">We conducted a systematic review of published articles on the prevalence of HBV infection in PLWHA in LAC countries or territories. Our review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement published in 2009 [<xref ref-type="bibr" rid="CR12">12</xref>] (Additional file <xref rid="MOESM1" ref-type="media">1</xref>).</p><sec id="Sec3"><title>Search strategies</title><p id="Par16">We searched Medline via the PubMed, Latin American and Caribbean Health Sciences (Literatura Latino-Americana e do Caribe em Ci&#x000ea;ncias da Sa&#x000fa;de&#x02013;Lilacs) via BVS, and Embase databases for studies up to November 2016 on infection with HIV and HBV in LAC without period and language restrictions. In Medline, we used the terms [(HIV OR Acquired Immunodeficiency Syndrome Virus OR AIDS OR HTLV OR Human Immunodeficiency Virus OR Human TCell) AND (HBV OR Hepatitis B OR Hepatitis B Virus) AND (name of each country or territory from LAC)]. In Lilacs, we used the terms [(HIV OR AIDS OR HUMAN IMMUNODEFICIENCY VIRUS) [Words] AND (HBV OR HEPATITIS B) [Words]]. In Embase, we searched the terms [(HIV OR AIDS OR HUMAN IMMUNODEFICIENCY VIRUS) AND (HBV OR HEPATITIS B)]. We manually searched the references of the selected studies and reviewed articles on the subjects to identify other relevant studies. Disagreements on the identification of relevant studies were discussed until a consensus was reached.</p><p id="Par17">The studies eligible for reading of the titles and abstracts were selected independently by two researchers (E.A. and M.N.), and a list of potentially relevant studies was generated. Articles for inclusion in the review were selected after reading the full text (A.A.B. and W.M.B.).</p><p id="Par18">The articles included were those that contained data on HBV infection in PLWHA, a serological diagnosis of HIV and HBV, and estimates of the prevalence of HBsAg in HIV-infected individuals.</p></sec><sec id="Sec4"><title>Study selection</title><p id="Par19">We included original articles that reported the prevalence of HBV in PLWHA in LAC with a sample size &#x02265;100. We did not include case reports, case series, review articles, comments, studies whose participants did not live in LAC, or studies that contained the same case series presented in other publications. Regarding the latter studies, the article with the most complete data was included in the study. We excluded self-reported HIV and/or HBV infections, data obtained from mandatory reporting of HIV and/or HBV (e.g., databases of the local Ministry of Health), and studies whose participant selection method was unclear.</p><p id="Par20">We used the following definitions: (1) HIV infection: the presence of anti-HIV antibodies measured by enzyme immunoassay; (2) HBV infection: the presence of HBsAg; and (3) Latin America and the Caribbean: the countries and territories of Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Aruba, Antigua and Barbuda, Aruba, Bahamas, Barbados, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Cura&#x000e7;ao, Dominica, Dominican Republic, Grenada, Guadalupe, Haiti, Jamaica, Martinique, Montserrat, Puerto Rico, Saba, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and The Grenadines, Sint Eustatius, Sint Maarten, Trinidad and Tobago, Turks and Caicos Islands, and the United States Virgin Islands.</p></sec><sec id="Sec5"><title>Data extraction</title><p id="Par21">Data were collected independently by two investigators (A.A.B. and W.M.B.), and disagreements were resolved via discussions and a consensus. The following data were collected from the articles: author name(s), year of publication, country (state in the case of Brazilian studies), period of data collection, type of study, sample size, mean age, gender of the participants, and number of HBsAg-positive individuals.</p><p id="Par22">Some studies did not report all of the variables necessary for the calculation of prevalence. In these cases, the missing variables were calculated using other reported values &#x0200b;&#x0200b;(e.g., the numerator was calculated from the values of the denominator and the prevalence).</p></sec><sec id="Sec6"><title>Quality assessment of the studies</title><p id="Par23">Based on the criteria proposed by Boyle [<xref ref-type="bibr" rid="CR13">13</xref>], Fowkes and Fulton [<xref ref-type="bibr" rid="CR14">14</xref>], Loney [<xref ref-type="bibr" rid="CR15">15</xref>], and Prins [<xref ref-type="bibr" rid="CR16">16</xref>], we created a list of criteria related to the <bold>adequacy of the sample</bold> (11 items: adequate design, prospective collection, definition of the target population, probability sampling, sample size calculation, inclusion and exclusion criteria, specification of the collection period, specification of the age range, adequate participant selection, acceptable sample loss, and sample representativeness), <bold>data collection</bold> (4 items: standardization of collection, clear definition of the outcome, definition of the outcome, and description of the outcome measurement), and <bold>data analysis and presentation</bold> (6 items: description of statistical analysis, total number of participants, number of events (outcomes), prevalence by sex and age, prevalence with confidence interval, and satisfactory confidence interval), for a total of 21 items. The items were scored as positive or negative, and the importance of each item was not weighted. Higher scores (positive items) corresponded to higher-quality studies for our review. This assessment was made independently by two researchers (E.A. and M.N.). Disagreements in the evaluation of the quality of the studies were discussed, and a consensus was reached.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par24">As a function of the expected heterogeneity among the selected studies, all meta-analyses were performed using random-effects models based on the DerSimonian and Laird method, which took into account variation among studies. Heterogeneity was assessed using Cochran&#x02019;s Q statistic (expressed as &#x003c7;2 and <italic>p</italic> values) and the I2 statistic, which described the percentage of variation among studies explained by heterogeneity rather than by chance. I2 values higher than 25%, 50%, and 75% are considered evidence of low, moderate, and high heterogeneity among studies, respectively. Low I2 values indicate that the variability among estimates is compatible with random variation. Additionally, we investigated potential sources of heterogeneity using a meta-regression analysis. The following factors were assessed using both uni- and multivariate models: publication year (comparison between studies published from 1999 to 2006 and those published from 2007 to 2016), geographical area (comparison between studies conducted in Brazil and elsewhere), study design (whether the data collection was cross-sectional or non-cross-sectional), sample size (continuous variable), and quality score (whether the quality score was &#x02264;10 or &#x0003e;10). We also performed an analysis considering two groups of studies: those published during the period from 1999 to 2006 and those published during the period from 2007 to 2016. In the studies published within the last ten years (2006 to 2016), we also analyzed the results stratified by sex and age group (&#x0003c;40&#x000a0;years and &#x02265;40&#x000a0;years). All analyses were performed using Stata version 13 (Stat Corp LP, TX, USA) with the commands <bold>metan</bold> (for the random-effects meta-analysis) and <bold>metareg</bold> (for the meta-regression).</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par25">We identified 1304 publications in Medline, Lilacs, and Embase, and no additional articles were found by the manual search (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). After excluding duplicates (80), 1224 articles were selected for reading of the titles and abstracts.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of the identification, inclusion, and exclusion of the studies</p></caption><graphic xlink:href="12879_2017_2695_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par26">After reading, 1151 articles were excluded, and 73 articles were selected for reading of the full text. Of these, we selected 28 articles (<italic>n</italic>&#x000a0;=&#x000a0;18,457) published from 1999 to 2016 for data extraction.</p><p id="Par27">Of the 28 publications on the prevalence of infection with HBV in PLWHA, 18 studies (64.3%) were from Brazil, 3 (10.7%) were from Argentina, 2 (7.1%) were from Chile, 2 (7.1%) were from Cuba, 1 (3.6%) was from Colombia, 1 (3.6%) was from Venezuela, and 1 (3.6%) was from Jamaica (Table <xref rid="Tab1" ref-type="table">1</xref>). The sample sizes ranged from 129 to 2994 participants (mean: 659; median: 471). The mean score of the study quality assessment was 11.6 (range: 8&#x02013;16). No study was scored &#x02264;7, 25 studies (89.3%) had scores between 8 and 14, and 3 (10.7%) studies had scores between 15 and 21 (maximum score: 21). The most common reasons precluding higher scores were the methods used for sample selection and the presentation of the results (the details of the quality assessment of the studies are shown in the Additional files <xref rid="MOESM2" ref-type="media">2</xref> and <xref rid="MOESM3" ref-type="media">3</xref>). The characteristics of the studies and the sample populations are shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Prevalence studies of HBsAg in people living with HIV/AIDS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Author</th><th>Year</th><th>Geographical region</th><th>Collection period</th><th>Study design</th><th>Total</th><th>Mean age</th><th>Gender (% M)</th><th>Outcome</th><th>HBsAg&#x000a0;+&#x000a0;(%)</th><th>Quality assessment</th></tr></thead><tbody><tr><td>Oliveira et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td>2016</td><td>Brazil</td><td>2009&#x02013;2010</td><td>Cross-sectional</td><td>505</td><td>37.6</td><td>60.2</td><td>25</td><td>4.9</td><td>15</td></tr><tr><td>Brandao et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td>2015</td><td>Brazil</td><td>2011</td><td>Cross-sectional</td><td>495</td><td>40</td><td>73.9</td><td>19</td><td>3.8</td><td>14</td></tr><tr><td>Vieira et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td>2015</td><td>Brazil</td><td>2008&#x02013;2009</td><td>Cross-sectional</td><td>297</td><td>NA</td><td>49.8</td><td>8</td><td>2.6</td><td>10</td></tr><tr><td>Martins et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td>2014</td><td>Brazil</td><td>2012&#x02013;2013</td><td>Cross-sectional</td><td>300</td><td>44.6</td><td>59.7</td><td>7</td><td>2.3</td><td>14</td></tr><tr><td>Bautista-Amorocho et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>2014</td><td>Colombia</td><td>2009&#x02013;2010</td><td>Cross-sectional</td><td>275</td><td>37.4</td><td>65.1</td><td>9</td><td>3.3</td><td>13</td></tr><tr><td>Jasper et al. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td>2014</td><td>Venezuela</td><td>2002&#x02013;2011</td><td>Retrospective</td><td>418</td><td>NA</td><td>64.1</td><td>13</td><td>3.1</td><td>10</td></tr><tr><td>Freitas et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>2014</td><td>Brazil</td><td>2009&#x02013;2011</td><td>Cross-sectional</td><td>848</td><td>41.6</td><td>57</td><td>21</td><td>2.5</td><td>13</td></tr><tr><td>Oliveira et al. [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td>2014</td><td>Brazil</td><td>2006&#x02013;2008</td><td>Cross-sectional</td><td>768</td><td>NA</td><td>65.4</td><td>46</td><td>6</td><td>11</td></tr><tr><td>Otto-Knapp et al. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td>2013</td><td>Chile</td><td>2001&#x02013;2007</td><td>Retrospective</td><td>1907</td><td>37.2</td><td>84.8</td><td>161</td><td>8.5</td><td>12</td></tr><tr><td>Tornatore et al. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td>2012</td><td>Brazil</td><td>2006&#x02013;2008</td><td>Cross-sectional</td><td>130</td><td>26.2</td><td>0</td><td>3</td><td>2.3</td><td>10</td></tr><tr><td>Benzaken et al. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>2012</td><td>Brazil</td><td>2009</td><td>Cross-sectional</td><td>598</td><td>29</td><td>47.7</td><td>35</td><td>5.9</td><td>16</td></tr><tr><td>Laufer et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td>2010</td><td>Argentina</td><td>2004&#x02013;2005</td><td>Cross-sectional</td><td>593</td><td>38</td><td>65.6</td><td>20</td><td>3.3</td><td>11</td></tr><tr><td>Perez et al. [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td>2009</td><td>Chile</td><td>1990&#x02013;2007</td><td>Retrospective</td><td>311</td><td>40.9</td><td>90.9</td><td>19</td><td>6.1</td><td>9</td></tr><tr><td>Sampaio et al. [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td>2009</td><td>Brazil</td><td>2004</td><td>Cross-sectional</td><td>429</td><td>39.3</td><td>60.1</td><td>44</td><td>10.3</td><td>13</td></tr><tr><td>Zago et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td>2007</td><td>Brazil</td><td>1993&#x02013;2004</td><td>Retrospective</td><td>851</td><td>35</td><td>52.1</td><td>32</td><td>3.8</td><td>13</td></tr><tr><td>Quarleri et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>2007</td><td>Argentina</td><td>2004&#x02013;2005</td><td>Cross-sectional</td><td>593</td><td>39</td><td>66</td><td>22</td><td>3.7</td><td>11</td></tr><tr><td>Braga et al. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td>2006</td><td>Brazil</td><td>1998&#x02013;2003</td><td>Retrospective</td><td>704</td><td>NA</td><td>65.1</td><td>45</td><td>6.4</td><td>12</td></tr><tr><td>Tovo et al. [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td>2006</td><td>Brazil</td><td>NA</td><td>Retrospective</td><td>343</td><td>34.4</td><td>62.4</td><td>14</td><td>4.6</td><td>10</td></tr><tr><td>Grinsztejn et al. [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td>2006</td><td>Brazil</td><td>1996&#x02013;2004</td><td>Cross-sectional</td><td>458</td><td>35.4</td><td>0</td><td>8</td><td>1.9</td><td>9</td></tr><tr><td>Pereira et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td>2006</td><td>Brazil</td><td>2004</td><td>Cross-sectional</td><td>1000</td><td>37.2</td><td>53</td><td>37</td><td>3.7</td><td>13</td></tr><tr><td>Corredor et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td>2005</td><td>Cuba</td><td>2000&#x02013;2004</td><td>Retrospective</td><td>2994</td><td>NA</td><td>NA</td><td>309</td><td>10.3</td><td>8</td></tr><tr><td>Monteiro et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td>2004</td><td>Brazil</td><td>1999&#x02013;2004</td><td>Cross-sectional</td><td>406</td><td>34.2</td><td>NA</td><td>32</td><td>7.9</td><td>15</td></tr><tr><td>Souza et al. [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td>2004</td><td>Brazil</td><td>1992&#x02013;1995</td><td>Retrospective</td><td>401</td><td>NA</td><td>64.8</td><td>34</td><td>8.5</td><td>13</td></tr><tr><td>Pavan et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td>2003</td><td>Brazil</td><td>1992&#x02013;1995</td><td>Retrospective</td><td>232</td><td>30.8</td><td>69.4</td><td>12</td><td>5.3</td><td>10</td></tr><tr><td>Smikle et al. [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td>2003</td><td>Jamaica</td><td>2001&#x02013;2002</td><td>Retrospective</td><td>129</td><td>NA</td><td>38</td><td>19</td><td>15</td><td>10</td></tr><tr><td>Mendes-Correa et al. [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td>2000</td><td>Brazil</td><td>1996</td><td>Retrospective</td><td>1693</td><td>NA</td><td>68.2</td><td>96</td><td>5.7</td><td>10</td></tr><tr><td>Rodriguez et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>2000</td><td>Cuba</td><td>NA</td><td>Cross-sectional</td><td>295</td><td>30</td><td>72.5</td><td>15</td><td>5.1</td><td>10</td></tr><tr><td>Fainboim et al. [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td>1999</td><td>Argentina</td><td>1994&#x02013;1995</td><td>Cross-sectional</td><td>484</td><td>29</td><td>74.2</td><td>70</td><td>14.5</td><td>10</td></tr></tbody></table></table-wrap>
</p><p id="Par28">The estimated prevalence of HBsAg in the 28 selected studies in LAC ranged from 2.0% (95% CI 1.0&#x02013;5.0%) to 15.0% (95% CI 9.0&#x02013;24.0%); the pooled prevalence was 7.0% (95% CI 7.0&#x02013;7.0%). The heterogeneity found was substantial among the estimates (I2&#x000a0;=&#x000a0;88.4%, <italic>p</italic>&#x000a0;=&#x000a0;0.00) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Estimated pooled prevalence of HBsAg in the LAC region</p></caption><graphic xlink:href="12879_2017_2695_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par29">A possible source of heterogeneity may have been the period in which the selected studies were published (from 1999 to 2006 or 2007&#x02013;2016) (meta-regression coefficient: &#x02212;0.410846; <italic>p</italic>&#x000a0;=&#x000a0;0.033) (Table <xref rid="Tab2" ref-type="table">2</xref>). None of the other factors investigated was significantly associated with heterogeneity.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate meta-regression analysis of the prevalence of HBV infection among individuals living with HIV/AIDS</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Meta-regression coefficient</th><th>95% CI</th><th>P</th></tr></thead><tbody><tr><td>Publication year (1999&#x02013;2006 vs. 2007&#x02013;2016)</td><td>&#x02212;0.410846</td><td>&#x02212;0.789861 to &#x02212;0.032406</td><td>0.033</td></tr><tr><td>Country (Brazil vs. other)</td><td>&#x02212;0.3252341</td><td>&#x02212;0.7287418 to 0.0782735</td><td>0.114</td></tr><tr><td>Data collection (cross-sectional vs. other)</td><td>&#x02212;0.3525707</td><td>&#x02212;0.7476732 to 0.0425319</td><td>0.080</td></tr><tr><td>Sample size</td><td>&#x02212;0.0002151</td><td>&#x02212;0.0000918 to 0.000522</td><td>0.170</td></tr><tr><td>Quality score</td><td>&#x02212;0.0212113</td><td>&#x02212;0.1197399 to 0.0773112</td><td>0.673</td></tr></tbody></table></table-wrap>
</p><p id="Par30">Figure <xref rid="Fig3" ref-type="fig">3</xref> shows that the estimated pooled prevalence of HBsAg was 8.0% (95% CI 8.0&#x02013;9.0%) in the 12 studies published from 1999 to 2006 and 6.0% (95% CI 5.0&#x02013;6.0%) in the remaining selected studies published from 2007 to 2016 (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Considering the second study period (2007 to 2016), the estimated prevalence of HBsAg for males in seven selected studies ranged from 3.0% (95% CI 1.0&#x02013;8.0%) to 10.0% (95% CI 8&#x02013;11%); the pooled prevalence was 8.0% (95% CI 7.0&#x02013;9.0%) (Additional file <xref rid="MOESM4" ref-type="media">4</xref>). For females (8 studies), the estimated prevalence of HBsAg ranged from 1.0% (95% CI 0.0&#x02013;5.0%) to 4.0% (95% CI 3.0&#x02013;8.0%); the pooled prevalence was 2.0% (95% CI 2.0&#x02013;3.0%) (Additional file <xref rid="MOESM5" ref-type="media">5</xref>). For the participants aged &#x02265;40&#x000a0;years (3 studies), the pooled prevalence was 5.0% (95% CI 4.0&#x02013;6.0%) (Additional file <xref rid="MOESM6" ref-type="media">6</xref>), whereas in participants younger than 40, the pooled prevalence was 3.0% (95% CI 2.0&#x02013;4.0%) (Additional file <xref rid="MOESM7" ref-type="media">7</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Estimated pooled prevalence of HBsAg in the 12 studies published during the period from 1999 to 2006</p></caption><graphic xlink:href="12879_2017_2695_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Estimated pooled prevalence of HBsAg in the 16 studies published during the period from 1999 to 2006</p></caption><graphic xlink:href="12879_2017_2695_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par31">During the period from 1999 to 2006, 3 articles were published that analyzed the factors associated with HBV exposure. The factors most frequently associated with HBV infection were increasing age and homosexuality. During the later period (2007 to 2016), six studies performed the same analysis. The factors most frequently associated with HBV were the male sex, increasing age, intravenous drug use, and a history of sexually transmitted diseases.</p></sec><sec id="Sec9"><title>Discussion</title><p id="Par32">HBV infection is one of the leading causes of morbidity and mortality among people living with HIV/AIDS and other populations with immune deficiencies. In our review of the results of the available studies, we attempted to present a comprehensive overview of the literature on the subject and gain new insights into the distribution of HBsAg among PLWHA.</p><p id="Par33">We systematically reviewed the studies conducted in LAC and found 28 studies from 7 countries (<italic>n</italic>&#x000a0;=&#x000a0;18,457). Our review indicated that the pooled prevalence of hepatitis B in PLWHA in LAC was approximately 7.0%. In studies published during the last 10&#x000a0;years, the estimated pooled prevalence of HBsAg among PLWHA was 6.0%. During the latter period, the prevalence of HBsAg in male participants and participants aged &#x02265;40&#x000a0;years was higher than the prevalence in women and in participants younger than 40&#x000a0;years of age.</p><p id="Par34">We did not find any review study on the prevalence of hepatitis B among PLWHA in LAC. In areas of low endemicity, such as the United States and Europe, HBV and HIV are usually acquired in adulthood by sexual and percutaneous transmission [<xref ref-type="bibr" rid="CR17">17</xref>]. In these regions, the prevalence of HBV coinfection among individuals with HIV varies from 5% to 10% depending on the route of infection. Konopnicki et al. [<xref ref-type="bibr" rid="CR2">2</xref>] reported data on the prevalence of HBsAg in the EuroSIDA study. This prospective observational cohort study evaluated patients with HIV-1 from 72 centers located in Europe and, more recently, in Argentina and Israel. The authors found that 498 of 5728 patients (8.7%) were positive for HBsAg. The highest prevalence rates for HBsAg were found in Argentina (17.8%), northern and central Europe (9.1%), southern Europe (8.9%), and eastern Europe (5.9%). This result suggests that the prevalence of chronic hepatitis B in this group is 100-fold higher than the prevalence in the general population [<xref ref-type="bibr" rid="CR2">2</xref>]. A study of patients with HIV infection from 11 geographic regions in the United States [<xref ref-type="bibr" rid="CR11">11</xref>] indicated that the HBsAg prevalence was 7.6%, and it was higher in male homosexuals than in heterosexuals; moreover, the prevalence of HBV was 2.3% in participants who used antiretroviral drugs containing lamivudine and 7.8% among participants who did not use lamivudine. In countries with intermediate and high endemicity, the main transmission routes were perinatal and during childhood. Generally, HBV infection precedes HIV infection by decades [<xref ref-type="bibr" rid="CR17">17</xref>]. In the endemic area of Sub-Saharan Africa, HBsAg is found in up to 36% of the HIV-infected population [<xref ref-type="bibr" rid="CR18">18</xref>]. The authors of one systematic review investigated the prevalence of hepatitis B and C in Sub-Saharan Africa and found rates ranging from 1.1% to 35.7%. The highest rates &#x0200b;&#x0200b;were found in western African regions (Nigeria, Ghana, Ivory Coast, Gambia, and Burkina Faso). In a study conducted in patients from the TREAT Asia HIV Observational Database (TAHOD), which involved a multicenter cohort of patients with HIV in the Asia-Pacific region, the authors reported that 10.4% (591/5656) of the participants were HBsAg-positive [<xref ref-type="bibr" rid="CR19">19</xref>]. A study conducted in China evaluated the prevalence of hepatitis B in 1958 HIV-infected patients [<xref ref-type="bibr" rid="CR20">20</xref>]. Of the 1958 patients, 186 (9.5%) were HBsAg-positive. The rates varied widely depending on the studied region of the country; the participants from the eastern region had the highest prevalence (14.5%), whereas those from the central region had the lowest prevalence (5.0%).</p><p id="Par35">Both tropical and central Latin America exhibited a significant decrease in the prevalence of HBsAg between 1990 and 2005 [<xref ref-type="bibr" rid="CR21">21</xref>]. Tropical Latin America (Brazil and Paraguay) was reclassified from an intermediate endemicity region to a low endemicity region. Similarly, the prevalence in central Latin America (Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, and Venezuela) decreased during this period, and a shift to low endemicity was observed for most age groups in 2005. In other regions, such as Andean Latin America (Bolivia, Ecuador, and Peru) and South Latin America (Argentina, Chile, and Uruguay), the endemicity levels remained intermediate even though the prevalence decreased with age.</p><p id="Par36">The heterogeneity of the data on the prevalence of HBsAg in PLWHA also significantly limited the interpretation of the results. However, the analysis shown in Table <xref rid="Tab3" ref-type="table">3</xref> (prevalence of HBsAg in the general population in selected countries based on data by Schweitzer et al. [<xref ref-type="bibr" rid="CR22">22</xref>]) indicated that the actual prevalence of HBsAg in PLWHA was highly likely to be greater than the prevalence in the general population. The reported prevalence in studies published during the last ten years (Fig. <xref rid="Fig4" ref-type="fig">4</xref>) suggests that the prevalence of HBsAg among PLWHA is on average 6.7 times (range: 1.5 to 15.9) higher than that in the general population. Additionally, the overall prevalence of HBsAg in Brazil, Colombia, and Venezuela decreased when comparing the data from 1990 and 2005 [<xref ref-type="bibr" rid="CR21">21</xref>]. The countries shifted from an intermediate endemicity region (2&#x02013;8%) to a low endemicity region (&#x0003c;2%), likely due to the implementation of vaccination against hepatitis B in children younger than 1&#x000a0;year of age in 1998. However, the prevalence of HBsAg in PLWHA appeared to remain between 2% and 8%.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Prevalence of HBsAg in the general population in the selected countries according to Schweitzer et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Prevalence of HBsAg</th></tr><tr><th>Country</th><th>%</th><th>95% CI</th></tr></thead><tbody><tr><td>Argentina</td><td>0.77%</td><td>0.77&#x02013;0.78</td></tr><tr><td>Brazil</td><td>0.65%</td><td>0.65&#x02013;0.66</td></tr><tr><td>Chile</td><td>0.68%</td><td>0.34&#x02013;1.35</td></tr><tr><td>Colombia</td><td>2.29%</td><td>1.86&#x02013;2.82</td></tr><tr><td>Cuba</td><td>1.30%</td><td>0.62&#x02013;2.70</td></tr><tr><td>Jamaica</td><td>3.76%</td><td>2.65&#x02013;5.29</td></tr><tr><td>Venezuela</td><td>0.48%</td><td>0.44&#x02013;0.52</td></tr></tbody></table></table-wrap>
</p><p id="Par37">The available data from the last 10&#x000a0;years showed that male individuals aged &#x02265;40&#x000a0;years were the most affected by HBV infection. Age is a known risk factor associated with HBV, likely due to increasing exposure over time. We observed that the male sex was also a risk factor, likely due to the more frequent exposure to risk factors involved in HBV transmission, especially sexual contact.</p><p id="Par38">The results of this review indicate that the prevention of HBV infection in PLWHA and HIV infection in the population with chronic hepatitis B has not been effective in LAC. Of the known strategies to prevent HBV infection, the most efficient is universal vaccination. In addition to immunization against hepatitis B, active recognition of chronic hepatitis B carriers is necessary. This measure is necessary to allow this population to receive specific treatment and to prevent the progression to well-known complications, which are more severe and rapidly progressive in patients with immunodeficiency, and the spread of infection, which is transmitted primarily via the sexual and vertical routes.</p><p id="Par39">This study has limitations. Studies on the prevalence of HBsAg are unavailable in various regions. Population-based studies are rare in all LAC regions, including areas in which the prevalence of HBsAg in the general population is at the intermediate level of endemicity, such as Belize (4.71%), the Dominican Republic (4.09%), Jamaica (3.76%), and Suriname (3.9%), and those with high levels of endemicity, such as Haiti (13.55%) [<xref ref-type="bibr" rid="CR22">22</xref>]. Thus, more studies are necessary to elucidate &#x0200b;&#x0200b;the burden of coinfection with HIV and HBV in LAC. However, our results indicate the need to increase the investment in preventive measures against hepatitis B, particularly when the impact of adequate vaccination in this population is considered.</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par40">The estimated pooled prevalence of HBsAg among PLWHA in the selected studies was 7.0% (95% CI 7.0&#x02013;7.0%), and the prevalence was 6.0% in the studies published within the last 10&#x000a0;years. The heterogeneity found was substantial among the estimates (I2&#x000a0;=&#x000a0;88.4%, <italic>p</italic>&#x000a0;=&#x000a0;0.00). A possible source of heterogeneity was the period in which the selected studies were published (from 1999 to 2006 or 2007&#x02013;2016) (meta-regression coefficient: &#x02212;0.410846; <italic>p</italic>&#x000a0;=&#x000a0;0.033).</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec11"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12879_2017_2695_MOESM1_ESM.pdf"><label>Additional file 1:</label><caption><p>Prisma 2009 Checklist. (PDF 85&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12879_2017_2695_MOESM2_ESM.pdf"><label>Additional file 2:</label><caption><p>Instrument for the assessment of the quality of the studies. Describes the items considered for the assessment of the quality of the studies. (PDF 64&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12879_2017_2695_MOESM3_ESM.pdf"><label>Additional file 3:</label><caption><p>Assessment of the quality of the studies. Contains data corresponding to the quality of the studies that describe their (quality) total score relative to the following items: sampling process, procedures used for data collection, and data analysis and description. (PDF 68&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12879_2017_2695_MOESM4_ESM.pdf"><label>Additional file 4:</label><caption><p>Estimated pooled prevalence of HBsAg in males during the period from 2007 to 2016 in Latin America and the Caribbean. (PDF 276&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12879_2017_2695_MOESM5_ESM.pdf"><label>Additional file 5:</label><caption><p>Estimated pooled prevalence of HBsAg in women during the period from 2007 to 2016 in Latin America and the Caribbean. (PDF 362&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12879_2017_2695_MOESM6_ESM.pdf"><label>Additional file 6:</label><caption><p>Estimated pooled prevalence of HBsAg in individuals aged 40&#x000a0;years and over during the period from 2007 to 2016 in Latin America and the Caribbean. (PDF 309&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="12879_2017_2695_MOESM7_ESM.pdf"><label>Additional file 7:</label><caption><p>Estimated pooled prevalence of HBsAg in individuals under 40&#x000a0;years of age during the period from 2007 to 2016 in Latin America and the Caribbean. (PDF 259&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AIDS</term><def><p id="Par5">Acquired immune deficiency syndrome</p></def></def-item><def-item><term>HBV</term><def><p id="Par6">Hepatitis B virus</p></def></def-item><def-item><term>HIV</term><def><p id="Par7">Human immunodeficiency virus</p></def></def-item><def-item><term>LAC</term><def><p id="Par8">Latin America and the Caribbean</p></def></def-item><def-item><term>PLHA</term><def><p id="Par9">People living with HIV/acquired immune deficiency syndrome</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12879-017-2695-z) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par41">The authors declare that they did not receive any funding for this research.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par42">All data analyzed during this study are included in this published article (and its supplementary information files) and are available from the included studies, which are fully referenced.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>FMT was responsible for the study design, data analysis, interpretation, and drafting of the manuscript. EA and MN performed the searches in the databases and selected articles based on their titles and abstracts, and MN assessed the quality of the studies. WMB and AAB selected the studies included in the review, extracted data from the selected articles based on a full-text analysis, contributed to the data analysis and interpretation and were responsible for the critical revision of the manuscript content. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par43">No ethical approval was sought, because approval was deemed unnecessary for this systematic review.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par44">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par45">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par46">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te</surname><given-names>HS</given-names></name><name><surname>Jensen</surname><given-names>DM</given-names></name></person-group><article-title>Epidemiology of hepatitis B and C viruses: a global overview</article-title><source>Clin Liver Dis</source><year>2010</year><volume>14</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2009.11.009</pub-id><?supplied-pmid 20123436?><pub-id pub-id-type="pmid">20123436</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konopnicki</surname><given-names>D</given-names></name><name><surname>Mocroft</surname><given-names>A</given-names></name><name><surname>de Wit</surname><given-names>S</given-names></name><name><surname>Antunes</surname><given-names>F</given-names></name><name><surname>Ledergerber</surname><given-names>B</given-names></name><name><surname>Katlama</surname><given-names>C</given-names></name><etal/></person-group><article-title>Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort</article-title><source>AIDS</source><year>2005</year><volume>19</volume><fpage>593</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000163936.99401.fe</pub-id><?supplied-pmid 15802978?><pub-id pub-id-type="pmid">15802978</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodsworth</surname><given-names>NJ</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name><name><surname>Donovan</surname><given-names>B</given-names></name></person-group><article-title>The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state</article-title><source>J Infect Dis</source><year>1991</year><volume>163</volume><fpage>1138</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1093/infdis/163.5.1138</pub-id><?supplied-pmid 2019762?><pub-id pub-id-type="pmid">2019762</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puoti</surname><given-names>M</given-names></name><name><surname>Torti</surname><given-names>C</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Filice</surname><given-names>G</given-names></name><name><surname>Carosi</surname><given-names>G</given-names></name></person-group><article-title>Natural history of chronic hepatitis B in co-infected patients</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><fpage>S65</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.11.015</pub-id><?supplied-pmid 16338021?><pub-id pub-id-type="pmid">16338021</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thio</surname><given-names>CL</given-names></name></person-group><article-title>Hepatitis B and human immunodeficiency virus coinfection</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>S138</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1002/hep.22883</pub-id><?supplied-pmid 19399813?><pub-id pub-id-type="pmid">19399813</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colin</surname><given-names>JF</given-names></name><name><surname>Cazals-Hatem</surname><given-names>D</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name><name><surname>Martinot-Peignoux</surname><given-names>M</given-names></name><name><surname>Pham</surname><given-names>BN</given-names></name><name><surname>Auperin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men</article-title><source>Hepatology</source><year>1999</year><volume>29</volume><fpage>1306</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1002/hep.510290447</pub-id><?supplied-pmid 10094979?><pub-id pub-id-type="pmid">10094979</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Martino</surname><given-names>V</given-names></name><name><surname>Thevenot</surname><given-names>T</given-names></name><name><surname>Colin</surname><given-names>JF</given-names></name><name><surname>Boyer</surname><given-names>N</given-names></name><name><surname>Martinot</surname><given-names>M</given-names></name><name><surname>Degos</surname><given-names>F</given-names></name><etal/></person-group><article-title>Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>1812</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.37061</pub-id><?supplied-pmid 12454838?><pub-id pub-id-type="pmid">12454838</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thio</surname><given-names>CL</given-names></name><name><surname>Seaberg</surname><given-names>EC</given-names></name><name><surname>Skolasky</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Phair</surname><given-names>J</given-names></name><name><surname>Visscher</surname><given-names>B</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>A</given-names></name><etal/></person-group><article-title>HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS)</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1921</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)11913-1</pub-id><?supplied-pmid 12493258?><pub-id pub-id-type="pmid">12493258</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eskild</surname><given-names>A</given-names></name><name><surname>Magnus</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name><name><surname>Sohlberg</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>F</given-names></name><name><surname>Kittelsen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS</article-title><source>AIDS</source><year>1992</year><volume>6</volume><fpage>571</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1097/00002030-199206000-00008</pub-id><?supplied-pmid 1388879?><pub-id pub-id-type="pmid">1388879</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>HM</given-names></name><name><surname>Roediger</surname><given-names>MP</given-names></name><name><surname>Hullsiek</surname><given-names>KH</given-names></name><name><surname>Thio</surname><given-names>CL</given-names></name><name><surname>Agan</surname><given-names>BK</given-names></name><name><surname>Bradley</surname><given-names>WP</given-names></name><etal/></person-group><article-title>Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir720</pub-id><?supplied-pmid 22147794?><pub-id pub-id-type="pmid">22147794</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellerman</surname><given-names>SE</given-names></name><name><surname>Hanson</surname><given-names>DL</given-names></name><name><surname>McNaghten</surname><given-names>AD</given-names></name><name><surname>Fleming</surname><given-names>PL</given-names></name></person-group><article-title>Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects</article-title><source>J Infect Dis</source><year>2003</year><volume>188</volume><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1086/377135</pub-id><?supplied-pmid 12898445?><pub-id pub-id-type="pmid">12898445</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>PRISMA group</collab></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>J Clin Epidemiol</source><year>2009</year><volume>62</volume><fpage>1006</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2009.06.005</pub-id><?supplied-pmid 19631508?><pub-id pub-id-type="pmid">19631508</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>MH</given-names></name></person-group><article-title>Guidelines for evaluating prevalence studies</article-title><source>Evid Based Ment Health</source><year>1998</year><volume>1</volume><fpage>37</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1136/ebmh.1.2.37</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowkes</surname><given-names>FG</given-names></name><name><surname>Fulton</surname><given-names>PM</given-names></name></person-group><article-title>Critical appraisal of published research: introductory guidelines</article-title><source>BMJ</source><year>1991</year><volume>302</volume><fpage>1136</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1136/bmj.302.6785.1136</pub-id><?supplied-pmid 2043787?><pub-id pub-id-type="pmid">2043787</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loney</surname><given-names>PL</given-names></name><name><surname>Chambers</surname><given-names>LW</given-names></name><name><surname>Bennett</surname><given-names>KJ</given-names></name><name><surname>Roberts</surname><given-names>JG</given-names></name><name><surname>Stratford</surname><given-names>PW</given-names></name></person-group><article-title>Critical appraisal of the health research literature: prevalence or incidence of a health problem</article-title><source>Chronic Dis Can</source><year>1998</year><volume>19</volume><fpage>170</fpage><lpage>176</lpage><?supplied-pmid 10029513?><pub-id pub-id-type="pmid">10029513</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>J</given-names></name><name><surname>Blanker</surname><given-names>MH</given-names></name><name><surname>Bohnen</surname><given-names>AM</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Bosch</surname><given-names>JL</given-names></name></person-group><article-title>Prevalence of erectile dysfunction: a systematic review of population-based studies</article-title><source>Int J Impot Res</source><year>2002</year><volume>14</volume><fpage>422</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/sj.ijir.3900905</pub-id><?supplied-pmid 12494273?><pub-id pub-id-type="pmid">12494273</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>MJ</given-names></name></person-group><article-title>Epidemiology of viral hepatitis and HIV co-infection</article-title><source>J Hepatol</source><year>2006</year><volume>44</volume><fpage>S6</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.11.004</pub-id><?supplied-pmid 16352363?><pub-id pub-id-type="pmid">16352363</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Geretti</surname><given-names>AM</given-names></name><name><surname>Goulder</surname><given-names>PJ</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name></person-group><article-title>Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in sub-Saharan Africa</article-title><source>J Clin Virol</source><year>2014</year><volume>61</volume><fpage>20</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.05.018</pub-id><?supplied-pmid 24973812?><pub-id pub-id-type="pmid">24973812</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>WW</given-names></name><name><surname>Law</surname><given-names>MG</given-names></name><name><surname>Kiertiburanakul</surname><given-names>S</given-names></name><name><surname>Yunihastuti</surname><given-names>E</given-names></name><name><surname>Merati</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV observational database: analysis of risk factors and survival</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0150512</pub-id><?supplied-pmid 26933963?><pub-id pub-id-type="pmid">26933963</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><etal/></person-group><article-title>Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study</article-title><source>J Int AIDS Soc</source><year>2016</year><volume>19</volume><fpage>20659</fpage><pub-id pub-id-type="doi">10.7448/IAS.19.1.20659</pub-id><?supplied-pmid 26979535?><pub-id pub-id-type="pmid">26979535</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>JJ</given-names></name><name><surname>Stevens</surname><given-names>GA</given-names></name><name><surname>Groeger</surname><given-names>J</given-names></name><name><surname>Wiersma</surname><given-names>ST</given-names></name></person-group><article-title>Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>2212</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.116</pub-id><?supplied-pmid 22273662?><pub-id pub-id-type="pmid">22273662</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schweitzer</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>J</given-names></name><name><surname>Mikolajczyk</surname><given-names>RT</given-names></name><name><surname>Krause</surname><given-names>G</given-names></name><name><surname>Ott</surname><given-names>JJ</given-names></name></person-group><article-title>Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>1546</fpage><lpage>1555</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)61412-X</pub-id><?supplied-pmid 26231459?><pub-id pub-id-type="pmid">26231459</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>MP</given-names></name><name><surname>Lemes</surname><given-names>PS</given-names></name><name><surname>Matos</surname><given-names>MA</given-names></name><name><surname>Del-Rios</surname><given-names>NH</given-names></name><name><surname>Carneiro</surname><given-names>MA</given-names></name><name><surname>Silva</surname><given-names>&#x000c1;M</given-names></name><etal/></person-group><article-title>Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil</article-title><source>J Med Virol</source><year>2016</year><volume>88</volume><fpage>1222</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1002/jmv.24462</pub-id><?supplied-pmid 27061406?><pub-id pub-id-type="pmid">27061406</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand&#x000e3;o</surname><given-names>NA</given-names></name><name><surname>Pfrimer</surname><given-names>IA</given-names></name><name><surname>Martelli</surname><given-names>CM</given-names></name><name><surname>Turchi</surname><given-names>MD</given-names></name></person-group><article-title>Prevalence of hepatitis B and C infection and associated factors in people living with HIV in Midwestern Brazil</article-title><source>Braz J Infect Dis</source><year>2015</year><volume>19</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2015.02.001</pub-id><?supplied-pmid 25766773?><pub-id pub-id-type="pmid">25766773</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>AC</given-names></name><name><surname>Tizzot</surname><given-names>MRPA</given-names></name><name><surname>Santos</surname><given-names>VLP</given-names></name><name><surname>Bovo</surname><given-names>F</given-names></name><name><surname>Reason</surname><given-names>IM</given-names></name></person-group><article-title>Epidemiological analysis of serological markers of hepatitis B in HIV+ patients from Curitiba and metropolitan region</article-title><source>J Bras Patol Med Lab</source><year>2015</year><volume>51</volume><fpage>17</fpage><lpage>21</lpage></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Martins S, Livramento Ad, Andrigueti M, Kretzer IF, Machado MJ, Spada C, et al. The prevalence of hepatitis B virus infection markers and socio-demographic risk factors in HIV-infected patients in Southern Brazil. Rev Soc Bras Med Trop. 2014;47:552&#x02013;558 doi:10.1590/0037-8682-0109-2014.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista-Amorocho</surname><given-names>H</given-names></name><name><surname>Castellanos-Dom&#x000ed;nguez</surname><given-names>YZ</given-names></name><name><surname>Rodr&#x000ed;guez-Villamizar</surname><given-names>LA</given-names></name><name><surname>Velandia-Cruz</surname><given-names>SA</given-names></name><name><surname>Becerra-Pe&#x000f1;a</surname><given-names>JA</given-names></name><name><surname>Farf&#x000e1;n-Garc&#x000ed;a</surname><given-names>AE</given-names></name></person-group><article-title>Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0114272</pub-id><?supplied-pmid 25462190?><pub-id pub-id-type="pmid">25462190</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaspe</surname><given-names>RC</given-names></name><name><surname>Sulbar&#x000e1;n</surname><given-names>YF</given-names></name><name><surname>Loureiro</surname><given-names>CL</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>N</given-names></name><name><surname>Devesa</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genetic diversity of hepatitis B virus and hepatitis C virus in human immunodeficiency virus type 1-co-infected patients from Venezuela</article-title><source>J Med Microbiol</source><year>2014</year><volume>63</volume><fpage>1099</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.067496-0</pub-id><?supplied-pmid 24895404?><pub-id pub-id-type="pmid">24895404</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>SZ</given-names></name><name><surname>Soares</surname><given-names>CC</given-names></name><name><surname>Tanaka</surname><given-names>TS</given-names></name><name><surname>Lindenberg</surname><given-names>AS</given-names></name><name><surname>Teles</surname><given-names>SA</given-names></name><name><surname>Torres</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Prevalence, risk factors and genotypes of hepatitis B infection among HIV-infected patients in the state of MS, central Brazil</article-title><source>Braz J Infect Dis</source><year>2014</year><volume>18</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/j.bjid.2014.01.005</pub-id><?supplied-pmid 24662138?><pub-id pub-id-type="pmid">24662138</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>EH</given-names></name><name><surname>Lima Verde</surname><given-names>RM</given-names></name><name><surname>Pinheiro</surname><given-names>LM</given-names></name><name><surname>Benchimol</surname><given-names>MG</given-names></name><name><surname>Arag&#x000e3;o</surname><given-names>AL</given-names></name><name><surname>Lemos</surname><given-names>JA</given-names></name><etal/></person-group><article-title>HBV infection in HIV-infected subjects in the state of Piaui, Northeast Brazil</article-title><source>Arch Virol</source><year>2014</year><volume>159</volume><fpage>1193</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1007/s00705-013-1921-2</pub-id><?supplied-pmid 24264385?><pub-id pub-id-type="pmid">24264385</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto-Knapp</surname><given-names>R</given-names></name><name><surname>Cortes</surname><given-names>CP</given-names></name><name><surname>Saavedra</surname><given-names>F</given-names></name><name><surname>Wolff</surname><given-names>M</given-names></name><name><surname>Weitzel</surname><given-names>T</given-names></name></person-group><article-title>Hepatitis B prevalence and influence on HIV treatment outcome and mortality in the Chilean AIDS cohort</article-title><source>Int J Infect Dis</source><year>2013</year><volume>17</volume><fpage>e919</fpage><lpage>e924</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2013.05.009</pub-id><?supplied-pmid 23849398?><pub-id pub-id-type="pmid">23849398</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornatore</surname><given-names>M</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>CV</given-names></name><name><surname>Bianchi</surname><given-names>MS</given-names></name><name><surname>Germano</surname><given-names>FN</given-names></name><name><surname>Garc&#x000e9;s</surname><given-names>AX</given-names></name><name><surname>Soares</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Co-infections associated with human immunodeficiency virus type 1 in pregnant women from southern Brazil: high rate of intraepithelial cervical lesions</article-title><source>Mem Inst Oswaldo Cruz</source><year>2012</year><volume>107</volume><fpage>205</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762012000200009</pub-id><?supplied-pmid 22415259?><pub-id pub-id-type="pmid">22415259</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzaken</surname><given-names>A</given-names></name><name><surname>Sabid&#x000f3;</surname><given-names>M</given-names></name><name><surname>Galban</surname><given-names>E</given-names></name><name><surname>Rodrigues Dutra</surname><given-names>DL</given-names></name><name><surname>Leturiondo</surname><given-names>AL</given-names></name><name><surname>Mayaud</surname><given-names>P</given-names></name></person-group><article-title>HIV and sexually transmitted infections at the borderlands: situational analysis of sexual health in the Brazilian Amazon</article-title><source>Sex Transm Infect</source><year>2012</year><volume>88</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1136/sextrans-2011-050309</pub-id><?supplied-pmid 22317841?><pub-id pub-id-type="pmid">22317841</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufer</surname><given-names>N</given-names></name><name><surname>Quarleri</surname><given-names>J</given-names></name><name><surname>Bouzas</surname><given-names>MB</given-names></name><name><surname>Juncos</surname><given-names>G</given-names></name><name><surname>Cabrini</surname><given-names>M</given-names></name><name><surname>Moretti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Hepatitis B virus, hepatitis C virus and HIV coinfection among people living with HIV/AIDS in Buenos Aires, Argentina</article-title><source>Sex Transm Dis</source><year>2010</year><volume>37</volume><fpage>342</fpage><lpage>343</lpage><?supplied-pmid 20351620?><pub-id pub-id-type="pmid">20351620</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez</surname><given-names>CC</given-names></name><name><surname>Cer&#x000f3;n</surname><given-names>AI</given-names></name><name><surname>Fuentes</surname><given-names>LG</given-names></name><name><surname>Za&#x000f1;artu</surname><given-names>SC</given-names></name><name><surname>Balcells</surname><given-names>MME</given-names></name><name><surname>Ajenjo</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Hepatitis B, C, Treponema pallidum and toxoplasma gondii co-infections in HIV infected patients</article-title><source>Rev Med Chil</source><year>2009</year><volume>137</volume><fpage>641</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">19701553</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Sampaio AS, de Alencar LCA, Moura P, Correia J, Barreto S, Castelo A. Prevalencia de la co-infecci&#x000f3;n con hepatitis B y C em pacientes HIV positivos y factores de riesgo associados. Actualizadiones en SIDA 2009;17:12&#x02013;17.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zago</surname><given-names>AM</given-names></name><name><surname>Machado</surname><given-names>TF</given-names></name><name><surname>Cazarim</surname><given-names>FL</given-names></name><name><surname>Miranda</surname><given-names>AE</given-names></name></person-group><article-title>Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitoria, Brazil</article-title><source>Braz J Infect Dis</source><year>2007</year><volume>11</volume><fpage>475</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702007000500007</pub-id><?supplied-pmid 17962873?><pub-id pub-id-type="pmid">17962873</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quarleri</surname><given-names>J</given-names></name><name><surname>Moretti</surname><given-names>F</given-names></name><name><surname>Bouzas</surname><given-names>MB</given-names></name><name><surname>Laufer</surname><given-names>N</given-names></name><name><surname>Carrillo</surname><given-names>MG</given-names></name><name><surname>Giuliano</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B</article-title><source>AIDS Res Hum Retrovir</source><year>2007</year><volume>23</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1089/aid.2006.0172</pub-id><?supplied-pmid 17506609?><pub-id pub-id-type="pmid">17506609</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>WS</given-names></name><name><surname>da Costa Castilho</surname><given-names>MDC</given-names></name><name><surname>dos Santos</surname><given-names>IC</given-names></name><name><surname>Moura</surname><given-names>MA</given-names></name><name><surname>Segurado</surname><given-names>AC</given-names></name></person-group><article-title>Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon Basin</article-title><source>Rev Soc Bras Med Trop</source><year>2006</year><volume>39</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1590/S0037-86822006000600001</pub-id><?supplied-pmid 17308694?><pub-id pub-id-type="pmid">17308694</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovo</surname><given-names>CV</given-names></name><name><surname>Dos Santos</surname><given-names>DE</given-names></name><name><surname>de Mattos</surname><given-names>AZ</given-names></name><name><surname>de Almeida</surname><given-names>PR</given-names></name><name><surname>de Mattos</surname><given-names>AA</given-names></name><name><surname>Santos</surname><given-names>BR</given-names></name></person-group><article-title>Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital</article-title><source>Arq Gastroenterol</source><year>2006</year><volume>43</volume><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1590/S0004-28032006000200002</pub-id><?supplied-pmid 17119657?><pub-id pub-id-type="pmid">17119657</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grinsztejn</surname><given-names>B</given-names></name><name><surname>Bastos</surname><given-names>FI</given-names></name><name><surname>Veloso</surname><given-names>VG</given-names></name><name><surname>Friedman</surname><given-names>RK</given-names></name><name><surname>Pilotto</surname><given-names>JH</given-names></name><name><surname>Schechter</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil</article-title><source>Int J STD AIDS</source><year>2006</year><volume>17</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1258/095646206777689071</pub-id><?supplied-pmid 16820078?><pub-id pub-id-type="pmid">16820078</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">de Almeida Pereira RADA, Mussi AD, de Azevedo e Silva VC, Souto FJ. Hepatitis B virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil. BMC Infect Dis. 2006;6:34 doi:10.1186/1471-2334-6-34.</mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Bello Corredor M, Rodr&#x000ed;guez Lay Lde L, Guti&#x000e9;rrez Moreno A, Sariego Fr&#x000f3;meta S, Montalvo Villalba MC, S&#x000e1;nchez Sol A. [Detection of hepatitis B and hepatitis C markers in HIV positive patients, 2000&#x02013;2004]. Rev Cuba Med Trop 2005;57:212&#x02013;213.</mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Monteiro MR, do Nascimento MM, Passos AD, Figueiredo JF. [Soroepidemiological survey of hepatitis B virus among HIV/AIDS patients in Bel&#x000e9;m, Par&#x000e1;--Brasil]. Rev Soc Bras Med Trop 2004;37:27&#x02013;32 doi:10.1590/S0037-86822004000700004.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>MG</given-names></name><name><surname>Passos</surname><given-names>AD</given-names></name><name><surname>Machado</surname><given-names>AA</given-names></name><name><surname>Figueiredo</surname><given-names>JF</given-names></name><name><surname>Esmeraldino</surname><given-names>LE</given-names></name></person-group><article-title>HIV and hepatitis B virus co-infection: prevalence and risk factors</article-title><source>Rev Soc Bras Med Trop</source><year>2004</year><volume>37</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1590/S0037-86822004000500004</pub-id><?supplied-pmid 15361955?><pub-id pub-id-type="pmid">15361955</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavan</surname><given-names>MHP</given-names></name><name><surname>Aoki</surname><given-names>FH</given-names></name><name><surname>Monteiro</surname><given-names>DT</given-names></name><name><surname>Gon&#x000e7;ales</surname><given-names>NSL</given-names></name><name><surname>Escanhoela</surname><given-names>CA</given-names></name><name><surname>Gon&#x000e7;ales J&#x000fa;nior</surname><given-names>FL</given-names></name></person-group><article-title>Viral hepatitis in patients infected with human immunodeficiency virus</article-title><source>Braz J Infect Dis</source><year>2003</year><volume>7</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1590/S1413-86702003000400005</pub-id><?supplied-pmid 14533986?><pub-id pub-id-type="pmid">14533986</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smikle</surname><given-names>MF</given-names></name><name><surname>Heslop</surname><given-names>O</given-names></name><name><surname>Vickers</surname><given-names>I</given-names></name><name><surname>Dowe</surname><given-names>G</given-names></name><name><surname>Deer</surname><given-names>D</given-names></name><name><surname>Sue-Ho</surname><given-names>R</given-names></name><etal/></person-group><article-title>A serosurvey of hepatitis B virus, hepatitis C virus, human T lymphotropic virus type-1 and syphilis in HIV-1-infected patients in Jamaica</article-title><source>West Indian Med J</source><year>2003</year><volume>52</volume><fpage>14</fpage><lpage>17</lpage><?supplied-pmid 12806748?><pub-id pub-id-type="pmid">12806748</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendes-Corr&#x000ea;a</surname><given-names>MC</given-names></name><name><surname>Barone</surname><given-names>AA</given-names></name><name><surname>Cavalheiro</surname><given-names>N</given-names></name><name><surname>Tengan</surname><given-names>FM</given-names></name><name><surname>Guastini</surname><given-names>C</given-names></name></person-group><article-title>Prevalence of hepatitis B and C in the sera of patients with HIV infection in Sao Paulo, Brazil</article-title><source>Rev Inst Med Trop Sao Paulo</source><year>2000</year><volume>42</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1590/S0036-46652000000200004</pub-id><?supplied-pmid 10810322?><pub-id pub-id-type="pmid">10810322</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>L</given-names></name><name><surname>Collado-Mesa</surname><given-names>F</given-names></name><name><surname>Arag&#x000f3;n</surname><given-names>U</given-names></name><name><surname>D&#x000ed;az</surname><given-names>B</given-names></name><name><surname>Rivero</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis B virus exposure in human immunodeficiency virus seropositive Cuban patients</article-title><source>Mem Inst Oswaldo Cruz</source><year>2000</year><volume>95</volume><fpage>243</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762000000200019</pub-id><?supplied-pmid 10733747?><pub-id pub-id-type="pmid">10733747</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainboim</surname><given-names>H</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>J</given-names></name><name><surname>Fassio</surname><given-names>E</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>A</given-names></name><name><surname>Otegui</surname><given-names>L</given-names></name><name><surname>Eposto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study</article-title><source>J Viral Hepat</source><year>1999</year><volume>6</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2893.1999.t01-1-6120135.x</pub-id><?supplied-pmid 10847130?><pub-id pub-id-type="pmid">10847130</pub-id></element-citation></ref></ref-list></back></article>